Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Experimental & Molecular Medicine
  • View all journals
  • Search
  • My Account Login
  • Content Explore content
  • About the journal
  • Publish with us
  • Sign up for alerts
  • RSS feed
  1. nature
  2. experimental & molecular medicine
  3. articles
  4. article
An alternatively spliced form of Met receptor is tumorigenic
Download PDF
Download PDF
  • Article
  • Open access
  • Published: 01 October 2006

An alternatively spliced form of Met receptor is tumorigenic

  • Jae-Ho Lee1,
  • Chong Feng Gao,
  • Chong Chou Lee,
  • Myung Deok Kim &
  • …
  • George F Vande Woude 

Experimental & Molecular Medicine volume 38, pages 565–573 (2006)Cite this article

  • 1530 Accesses

  • 50 Citations

  • Metrics details

Abstract

The Met tyrosine kinase receptor is a widely expressed molecule, which mediates pleiotropic cellular responses following activation by its ligand, hepatocyte growth factor/scatter factor (HGF/SF). Previously, one of the authors identified an alternatively spliced form of Met (Met-SM) that lacked a single exon of a 47-amino-acid segment in the juxtamembrane domain. Here we report that Met-SM is a potent transforming gene in NIH3T3 mouse fibroblast cells. Met-SM-transfected NIH3T3 cells show stronger foci-forming activity than wild type-Met-transfected ones. In addition, Met-SM-transfected NIH3T3 cells form colonies in soft agar and are tumorigenic in athymic nu/nu mice. Furthermore, HGF/SF significantly increases the focus-forming activity of Met-SM comparing to wild type Met. The amount of protein and of tyrosine kinase activity of Met-SM accumulates to a high level following HGF/SF treatment. The accumulation of Met-SM correlated well with its delayed ubiquitination and increased stability. These results are consistent with the important role of the juxtamembrane domain in protein stability of Met receptor and suggest that the alternatively-spliced form may contribute to the development and progression of human cancer.

Similar content being viewed by others

Structural basis of the activation of c-MET receptor

Article Open access 01 July 2021

SMAD4 mutations do not preclude epithelial–mesenchymal transition in colorectal cancer

Article Open access 03 December 2021

Fis1 phosphorylation by Met promotes mitochondrial fission and hepatocellular carcinoma metastasis

Article Open access 01 December 2021

Article PDF

Author information

Authors and Affiliations

  1. Department of Biochemistry, School of Medicine, Ajou University, Suwon, Korea

    Jae-Ho Lee

Authors
  1. Jae-Ho Lee
    View author publications

    Search author on:PubMed Google Scholar

  2. Chong Feng Gao
    View author publications

    Search author on:PubMed Google Scholar

  3. Chong Chou Lee
    View author publications

    Search author on:PubMed Google Scholar

  4. Myung Deok Kim
    View author publications

    Search author on:PubMed Google Scholar

  5. George F Vande Woude
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Lee, JH., Gao, C., Lee, C. et al. An alternatively spliced form of Met receptor is tumorigenic. Exp Mol Med 38, 565–573 (2006). https://doi.org/10.1038/emm.2006.66

Download citation

  • Published: 01 October 2006

  • Issue date: 01 October 2006

  • DOI: https://doi.org/10.1038/emm.2006.66

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Keywords

  • alternative splicing
  • hepatocyte growth factor
  • neoplasms
  • proto-oncogene proteins c-met

This article is cited by

  • MET exon 14 skipping mutation drives cancer progression and recurrence via activation of SMAD2 signalling

    • Qiaoyan Liang
    • Yajun Hu
    • Bing Zhao

    British Journal of Cancer (2024)

  • The role of RNA alternative splicing in regulating cancer metabolism

    • Itamar Kozlovski
    • Zahava Siegfried
    • Rotem Karni

    Human Genetics (2017)

  • 89Zr-Onartuzumab PET imaging of c-MET receptor dynamics

    • Martin Pool
    • Anton G. T. Terwisscha van Scheltinga
    • Marjolijn N. Lub-de Hooge

    European Journal of Nuclear Medicine and Molecular Imaging (2017)

  • Autoinhibition of the Ron receptor tyrosine kinase by the juxtamembrane domain

    • Xin Wang
    • Neela Yennawar
    • Pamela A Hankey

    Cell Communication and Signaling (2014)

Download PDF

Advertisement

Explore content

  • Research articles
  • Reviews & Analysis
  • News & Comment
  • Current issue
  • Collections
  • Sign up for alerts
  • RSS feed

About the journal

  • Special Feature
  • Journal Information
  • About the Editors
  • About the Partner
  • Contact
  • For Advertisers
  • Press Releases
  • Open Access Fees and Funding

Publish with us

  • For Authors & Referees
  • Language editing services
  • Open access funding
  • Submit manuscript

Search

Advanced search

Quick links

  • Explore articles by subject
  • Find a job
  • Guide to authors
  • Editorial policies

Experimental & Molecular Medicine (Exp Mol Med)

ISSN 2092-6413 (online)

ISSN 1226-3613 (print)

nature.com footer links

About Nature Portfolio

  • About us
  • Press releases
  • Press office
  • Contact us

Discover content

  • Journals A-Z
  • Articles by subject
  • protocols.io
  • Nature Index

Publishing policies

  • Nature portfolio policies
  • Open access

Author & Researcher services

  • Reprints & permissions
  • Research data
  • Language editing
  • Scientific editing
  • Nature Masterclasses
  • Research Solutions

Libraries & institutions

  • Librarian service & tools
  • Librarian portal
  • Open research
  • Recommend to library

Advertising & partnerships

  • Advertising
  • Partnerships & Services
  • Media kits
  • Branded content

Professional development

  • Nature Awards
  • Nature Careers
  • Nature Conferences

Regional websites

  • Nature Africa
  • Nature China
  • Nature India
  • Nature Japan
  • Nature Middle East
  • Privacy Policy
  • Use of cookies
  • Legal notice
  • Accessibility statement
  • Terms & Conditions
  • Your US state privacy rights
Springer Nature

© 2026 Springer Nature Limited